Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Diluted Average) (2020 - 2025)

Viridian Therapeutics, Inc.\DE has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $138875.0 for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $138875.0 for Q4 2025, down 10.32% from a year ago — trailing twelve months through Dec 2025 was $138875.0 (down 10.32% YoY), and the annual figure for FY2025 was $138875.0, down 10.32%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $138875.0 at Viridian Therapeutics, Inc.\DE, up from $134864.0 in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for VRDN hit a ceiling of $66.4 million in Q3 2024 and a floor of $66385.0 in Q4 2023.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $10.2 million (2021), compared with a mean of $22.1 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 312.32% in 2022 and later plummeted 99.8% in 2025.
  • Viridian Therapeutics, Inc.\DE's Shares Outstanding (Diluted Average) stood at $11.9 million in 2021, then tumbled by 98.3% to $203190.0 in 2022, then plummeted by 67.33% to $66385.0 in 2023, then soared by 133.27% to $154856.0 in 2024, then dropped by 10.32% to $138875.0 in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $138875.0 (Q4 2025), $134864.0 (Q3 2025), and $145160.0 (Q2 2025) per Business Quant data.